The Filing Desk

MeiraGTx vs Recursion Pharmaceuticals

MeiraGTx MGTX · Recursion Pharmaceuticals RXRX · Biotechnology

MeiraGTx reported revenue of $81 million in fiscal 2025, about the same as Recursion Pharmaceuticals' $75 million in fiscal 2025. MeiraGTx's revenue grew 144.6% in its latest year, and Recursion Pharmaceuticals' grew 26.9%. MeiraGTx had an operating margin of -130.2%, against -867.9% at Recursion Pharmaceuticals. Free cash flow was −$50 million at MeiraGTx and −$378 million at Recursion Pharmaceuticals.

Side by side

MeiraGTxRecursion Pharmaceuticals
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$81M$75M
Revenue growth144.6%26.9%
Revenue growth a year, last 5 years39.2%79.6%
Gross margin—5.0%
Operating margin−130.2%−867.9%
Net margin−140.3%−863.4%
Free cash flow−$50M−$378M
Free cash flow margin−61.7%−506.5%
Return on capital—−117.2%
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count15.2%63.2%
Last close$9.18$3.19
P/E at the last close11.5×—
Insider trades, last 12 months—sold $7.1 million
Piotroski F-score3 of 84 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
MeiraGTxRecursion Pharmaceuticals
Operating margin
Percent of revenue
MeiraGTxRecursion Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
MeiraGTxRecursion Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the MeiraGTx and Recursion Pharmaceuticals pages.